Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$7.82M-$7.82MN/M vs Q1 2021 EPS Diluted-$0.32-$0.32N/M vs Q1 2021 Operating Income-$7,831,534N/M Operating Cash Flow$24,046,566N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
Free Cash Flowderived$23,478,950N/M ended Mar 31, 2022 · filed May 11, 2022 · 41 d after period end